Top Page
OncoSil Medical Ltd
(Sydney:OSL)
OncoSil Medical Ltd (OSL) vs. iShares MSCI Australia ETF (EWA)
OncoSil Medical Ltd Business Overview & Revenue Model
OncoSil Medical Ltd Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.01M | 1.17M | 516.63K | 367.68K | 231.79K | 213.07K |
| Gross Profit | -4.06M | -1.08M | -993.00K | -1.22M | -6.73M | -748.00K |
| EBITDA | -15.08M | -15.06M | -12.91M | -11.17M | -11.41M | -11.31M |
| Net Income | -15.10M | -15.10M | -11.91M | -11.34M | -10.73M | -10.43M |
Balance Sheet | ||||||
| Total Assets | 7.15M | 7.15M | 6.72M | 11.47M | 13.07M | 14.15M |
| Cash, Cash Equivalents and Short-Term Investments | 5.11M | 5.11M | 4.50M | 9.39M | 11.28M | 12.24M |
| Total Debt | 69.92K | 69.92K | 70.67K | 170.81K | 304.21K | 484.37K |
| Total Liabilities | 4.04M | 4.04M | 1.98M | 1.59M | 1.91M | 2.45M |
| Stockholders Equity | 3.10M | 3.10M | 4.74M | 9.88M | 11.16M | 11.70M |
Cash Flow | ||||||
| Free Cash Flow | -12.08M | -12.08M | -11.02M | -11.37M | -10.12M | -8.87M |
| Operating Cash Flow | -12.06M | -12.06M | -10.82M | -11.32M | -10.11M | -8.82M |
| Investing Cash Flow | -14.96K | -14.96K | -197.06K | -57.82K | -5.83K | -54.00K |
| Financing Cash Flow | 12.73M | 12.73M | 6.13M | 9.49M | 9.16M | 111.25K |
OncoSil Medical Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | AU$24.72M | -2.58 | -103.74% | ― | 14.84% | 39.64% | |
46 Neutral | AU$106.69M | -7.95 | -31.98% | ― | 34.20% | -23.90% | |
44 Neutral | AU$168.22M | -15.78 | -70.55% | ― | ― | -257.32% | |
44 Neutral | AU$1.93B | -47.67 | -44.49% | ― | 55.91% | 22.60% | |
42 Neutral | AU$13.34M | -0.51 | -385.20% | ― | 126.62% | 33.53% | |
41 Neutral | AU$64.62M | -3.94 | -128.19% | ― | -14.25% | -22.83% |
OncoSil Medical Ltd Corporate Events
OncoSil Medical Ltd has updated details of its proposed non-renounceable pro rata issue of securities, lodging an amended Appendix 3B with the ASX. The company has revised the timetable for the offer, pushing back a key date from 12 March 2025 to 17 March 2025, and has also corrected the offer price of the retail offer options from $0.68 per security to $0.00, effectively indicating that the options will be issued at no subscription price. These changes clarify the commercial terms and timing of the capital raising structure, which may affect investor expectations and the attractiveness of participation in the retail component of the offer.
The most recent analyst rating on (AU:OSL) stock is a Sell with a A$0.80 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
OncoSil Medical Ltd has announced a proposed issue of up to 4,723,060 new fully paid ordinary shares under a placement or similar capital-raising mechanism, with an intended issue date of 9 February 2026. The additional securities, to be quoted on the ASX under code OSL, signal a move to raise fresh equity capital, which may impact the company’s capital structure and existing shareholders’ dilution while providing funding flexibility for its ongoing corporate and operational needs.
The most recent analyst rating on (AU:OSL) stock is a Sell with a A$0.80 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
OncoSil Medical Ltd has released a prospectus for a fully underwritten, non-renounceable pro-rata entitlement offer to raise up to approximately $2 million before costs, issuing one new share for every 6.4 shares held at $0.68 per share, with one new option attached to each new share. The capital raising structure also includes additional option offers to certain placement investors and to the lead manager, Bell Potter Securities, underscoring the company’s need for new funding while highlighting the speculative nature of the investment and the standard legal and risk disclaimers typical of such offers.
The most recent analyst rating on (AU:OSL) stock is a Sell with a A$0.80 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
OncoSil Medical has secured firm commitments for an $8 million capital raising, comprising a $6 million two-tranche placement to institutional and professional investors and a fully underwritten $2 million non-renounceable entitlement offer, both priced at $0.68 per share with attaching options. The raise, backed by substantial shareholders including Pengana High Conviction Equities Fund and with participation from directors, will lift pro forma cash to about $12 million to fund ongoing commercial roll-out, regulatory activities and key clinical milestones, notably a German government-sponsored G-BA trial involving around 40 hospitals set to begin recruiting in the first half of 2026, expected to generate trial-related revenues and support broader European reimbursement and guideline inclusion, while momentum continues in other European markets and label expansion submissions progress.
The most recent analyst rating on (AU:OSL) stock is a Sell with a A$0.80 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
OncoSil Medical reported strong early real-world clinical outcomes from Ankara Bilkent City Hospital in Türkiye, where six patients with unresectable locally advanced pancreatic cancer were treated with the OncoSil™ device alongside standard FOLFIRINOX chemotherapy. The cohort achieved one complete response, four partial responses and one stable disease case, with 83% of patients subsequently undergoing successful surgical resection with curative intent—a rate materially higher than published benchmarks for chemotherapy alone and previous OncoSil™ trial data. The company said these results underscore the potential of its device to significantly improve resection rates in a patient group that typically has limited options, bolstering its commercial strategy as it continues to drive broader international adoption and build real-world evidence to support wider clinical use.
The most recent analyst rating on (AU:OSL) stock is a Sell with a A$0.80 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
OncoSil Medical reported a pivotal second quarter of FY26, delivering record dose sales, with unit volumes up 60% and revenue rising 70% year-on-year, underscoring accelerating clinical adoption and strengthening market presence. The company completed its first commercial OncoSil™ treatments in Portugal, Germany and the UK, advanced European rollout with a successful production run at its new Sydney facility, received a $1.8 million R&D tax incentive to support ongoing development, reported encouraging real-world survival data from its OSPREY registry analysis, and announced the retirement of Non-Executive Director and former Chair Douglas Cubbin, collectively reinforcing its operational momentum and manufacturing capability in the pancreatic cancer treatment market.
The most recent analyst rating on (AU:OSL) stock is a Sell with a A$0.80 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
OncoSil Medical Ltd has requested an immediate trading halt in its securities on the ASX as it prepares to announce a capital raising. The halt will remain in place until the company releases details of the capital raising or until the start of normal trading on 3 February 2026, whichever comes first, signalling a pending move to secure new funding that could impact its capital structure and future operations.
The most recent analyst rating on (AU:OSL) stock is a Sell with a A$0.80 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
OncoSil Medical has completed the Last Patient, Last Visit milestone in its TRIPP-FFX clinical trial, a prospective multi-centre study assessing the safety and efficacy of the OncoSil™ device when used alongside FOLFIRINOX chemotherapy in patients with unresectable locally advanced pancreatic cancer. With 88 patients enrolled across 15 sites in Europe and Australia, the company will now move to final data cleaning, database lock and statistical analysis, and plans to present results in the first half of 2026, followed by a regulatory submission in the second half of 2026 to extend its CE Mark to include use with FOLFIRINOX. Together with completion of the PANCOSIL investigator-initiated study, this marks the end of a major phase of clinical investment in this indication and positions OncoSil to concentrate on regulatory engagement, potential label expansion and broader commercial execution, potentially giving clinicians more flexibility to integrate the device into standard treatment pathways for a high unmet-need cancer.
The most recent analyst rating on (AU:OSL) stock is a Hold with a A$0.76 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
OncoSil Medical has announced the first successful OncoSil™ treatment at Vivantes Neukölln Hospital in Berlin, one of the largest hospitals in Germany and a leading centre for gastrointestinal oncology within the country’s largest municipal hospital group. The hospital is the second in Germany to adopt the OncoSil™ device, marking a key milestone in the company’s expansion in a strategically important market with a high incidence of pancreatic cancer and a strong network of tertiary referral centres. The new site reinforces growing clinical interest in the therapy, supports OncoSil’s strategy to build clinical momentum and physician awareness ahead of an upcoming German reimbursement trial, and is expected to accelerate adoption across Germany and the wider European region.
The most recent analyst rating on (AU:OSL) stock is a Hold with a A$0.76 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
OncoSil Medical has completed the first treatment using its OncoSil™ device at Acibadem Maslak Hospital in Istanbul, marking a key milestone in its international expansion strategy. Türkiye, with around 8,500 new pancreatic cancer cases annually and a sophisticated, fast-adopting private healthcare sector, is seen as a strategically important growth market, and establishing clinical use at a flagship institution within the Acibadem Health Group is expected to build awareness, clinical momentum and broader regional uptake of the therapy for patients with unresectable locally advanced pancreatic cancer.
The most recent analyst rating on (AU:OSL) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
OncoSil Medical announced that a peer‑reviewed study in Gastrointestinal Endoscopy found that patients with locally advanced pancreatic cancer treated with the OncoSil™ phosphorus‑32 implant plus chemotherapy experienced better outcomes than those receiving chemotherapy alone, with improved overall survival, longer local progression‑free survival, higher rates of tumour downstaging and surgical resection, and a favourable safety profile in a 104‑patient analysis. The study, conducted by teams in Australia and New Zealand and accompanied by a positive independent editorial describing the results as “a signal worth pursuing,” strengthens the clinical evidence base for OncoSil™ therapy and supports the company’s ongoing clinical development efforts, potentially enhancing its positioning in the pancreatic cancer treatment landscape and offering encouraging signals for clinicians and patients facing limited options.
The most recent analyst rating on (AU:OSL) stock is a Sell with a A$1.00 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
OncoSil Medical has received a A$1.84 million refund under Australia’s R&D Tax Incentive program for eligible research and development activities conducted in the 2025 financial year, reinforcing government-backed support for its ongoing innovation in pancreatic cancer treatment. The company said the non-dilutive funding will help advance its commercial-stage OncoSil™ device, as management focuses on boosting clinician awareness and adoption to drive sales growth and shareholder value while maintaining fiscal discipline, underlining its efforts to strengthen its position in the niche market for localised pancreatic cancer therapies.
The most recent analyst rating on (AU:OSL) stock is a Sell with a A$1.00 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
OncoSil Medical Ltd, an ASX-listed oncology-focused medical company, develops and commercialises cancer treatment technologies and related medical devices.
The company has notified the cessation of 7,500 OSLAR options, which were due to expire in November 2028 with an exercise price of $12.00, after the conditional rights attached to these securities lapsed because the required conditions were not, or could no longer be, satisfied, resulting in a minor adjustment to the company’s issued capital structure.
The most recent analyst rating on (AU:OSL) stock is a Sell with a A$1.00 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
OncoSil Medical Limited has successfully completed its first hot production test run at its Sydney manufacturing facility, marking a significant milestone in its manufacturing capabilities. This achievement demonstrates the facility’s ability to produce the OncoSil™ device under full production conditions, supporting the company’s regulatory review process and strategy to enhance supply chain resilience. The new facility is expected to improve manufacturing efficiencies and reduce production costs, potentially increasing product margins, subject to regulatory approval and operational performance.
The most recent analyst rating on (AU:OSL) stock is a Sell with a A$1.00 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
OncoSil Medical Ltd announced the cessation of 17,076 ordinary fully paid securities due to the lapse of conditional rights, as the conditions for these securities were not met or became incapable of being satisfied. This development may impact the company’s capital structure and could have implications for its financial strategy and stakeholder interests.
The most recent analyst rating on (AU:OSL) stock is a Sell with a A$1.00 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
OncoSil Medical Limited has announced the first commercial use of its OncoSil™ device in the UK for treating unresectable locally advanced pancreatic cancer, marking a significant milestone in its commercial operations. This treatment, performed at Southampton General Hospital, transitions the company from clinical trials to commercial activity in the UK, targeting an addressable market opportunity of $138 million annually. The device is expected to benefit approximately 3,600 eligible patients per year in the UK, reinforcing OncoSil’s commitment to expanding access to innovative cancer treatments globally.
The most recent analyst rating on (AU:OSL) stock is a Sell with a A$1.00 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
OncoSil Medical Limited announced promising interim results from the OSPREY registry, showing improved survival rates for LAPC patients treated with the OncoSil™ device and chemotherapy. The findings indicate a significant survival advantage compared to standard chemotherapy alone, with a favorable safety profile, potentially impacting the company’s market position and offering hope for improved patient outcomes.
The most recent analyst rating on (AU:OSL) stock is a Sell with a A$1.00 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
OncoSil Medical Limited announced a change in the director’s interest, with Lelde Smits acquiring 41,067 shares in lieu of cash director fees for the period from October 2025 to September 2026. This move, approved by shareholders at the 2025 Annual General Meeting, reflects the company’s strategic approach to align director incentives with company performance, potentially impacting stakeholder confidence and the company’s market positioning.
The most recent analyst rating on (AU:OSL) stock is a Sell with a A$1.00 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
OncoSil Medical Ltd has announced the issuance of new unquoted equity securities, specifically options set to expire in 2028 and 2030, with an exercise price of $1.80. This move is likely to impact the company’s financial structure and could influence its market positioning by potentially increasing capital resources, thereby supporting its ongoing operations and strategic initiatives.
The most recent analyst rating on (AU:OSL) stock is a Sell with a A$1.00 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
OncoSil Medical Ltd has announced the application for quotation of 82,134 ordinary fully paid securities on the Australian Securities Exchange (ASX), following shareholder approval at the 2025 AGM. This move is part of the company’s strategic efforts to enhance its financial standing and operational capabilities, potentially impacting its market position and offering new opportunities for stakeholders.
The most recent analyst rating on (AU:OSL) stock is a Sell with a A$1.00 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
OncoSil Medical Ltd announced the cessation of Douglas Cubbin as a director of the company as of November 19, 2025. This change in the board may impact the company’s strategic direction and governance. The announcement also detailed Cubbin’s interests in the company’s securities, including the lapse of 12,500 unlisted options upon his departure. The update is significant for stakeholders as it reflects changes in leadership and potential shifts in company policy or focus.
The most recent analyst rating on (AU:OSL) stock is a Sell with a A$1.00 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
OncoSil Medical Ltd announced the cessation of 12,500 securities due to the lapse of conditional rights, as the conditions for these securities were not met. This development may impact the company’s financial structure and could influence investor perceptions, although the broader implications for stakeholders remain to be seen.
The most recent analyst rating on (AU:OSL) stock is a Sell with a A$1.00 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
OncoSil Medical Limited announced that its CEO, Nigel Lange, will present at the 2025 Bell Potter Healthcare Conference in Sydney, Australia. This presentation underscores OncoSil’s commitment to advancing its position in the medical device sector, particularly in the treatment of pancreatic cancer, and highlights the company’s ongoing efforts to expand its market presence and stakeholder engagement.
The most recent analyst rating on (AU:OSL) stock is a Sell with a A$1.00 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
OncoSil Medical Limited announced that all resolutions at its Annual General Meeting were approved by poll. This outcome reflects strong shareholder support for the company’s strategic direction and operational decisions, potentially reinforcing its position in the medical device industry focused on cancer treatment.
The most recent analyst rating on (AU:OSL) stock is a Sell with a A$1.00 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
OncoSil Medical Limited announced significant achievements in FY25, including regulatory progress and commercial expansion. The approval from Germany’s G-BA for a fully funded clinical trial is expected to enhance access to the OncoSil™ device in the German public hospital system, potentially influencing reimbursement negotiations across Europe. Additionally, the company achieved MDR certification, streamlining treatment initiation in the EU and UK, and recorded its first commercial sale in Germany. Clinical trials like PANCOSIL and TRIPP-FFX are nearing completion, with promising results supporting the efficacy of the OncoSil™ device.
The most recent analyst rating on (AU:OSL) stock is a Sell with a A$1.00 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.